AbbVie has continued its recent foray into sport by striking a partnership with Formula 1 (F1) team McLaren, reflecting a growing trend by the pharmaceutical industry to increase visibility via differing mediums as marketing tides shift.
The multi-year tie-up will see AbbVie become an official pharmaceutical partner to the McLaren Mastercard F1 team. The two will begin their work together – dubbed ‘Race to Innovate’ – at the US Grand Prix in Austin, Texas, taking place this weekend.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As part of the partnership, AbbVie will donate $10,000 to global charities for every 10 constructors’ championship points earned by McLaren. The number of points won by teams is tiered by finishing position in races. McLaren won the constructors championship in 2025, amassing 833 points.
AbbVie’s donation amount reflects the approximately 10% of people impacted by autoimmune diseases globally. Funds will support patient advocacy organisations and individuals living with immune-mediated disease.
Examples of immune-mediated diseases include rheumatoid arthritis, celiac disease, and multiple sclerosis.
Conrad Wiacek, head of sports analysis at GlobalData, said: “The deal between McLaren and AbbVie highlights another pharma company entering into sports sponsorship. While pharma deals are prevalent across US sports in particular given the nature of the healthcare industry in the US, with multiple deals already in place across different sports, entering into an F1 partnership gives AbbVie a global footprint.
“There is synergy between F1 and pharma, with technological innovation at the forefront of both industries, so being able to lean on this narrative for this partnership will be a crucial component of this deal.”
In 2027, Race to Innovate will be in place throughout the full F1 season. AbbVie will continue donating for the full season, alongside other immune disease-related engagement activities.
McLaren Racing’s co-chief commercial officer, Matt Dennington, said: “This partnership brings together two organisations that share a relentless pursuit of progress, whether that’s pushing the limits of performance on track or advancing life-changing science off it.”
Pharmaceutical and sport’s unlikely marriage
For AbbVie, its drive into F1 marks a continuation of efforts to increase its visibility within sport. In March this year, the drugmaker became the official partner of Major League Baseball (MLB). As per that cancer-driven partnership, AbbVie is donating $20 for every strikeout, up to a maximum donation of $1m per season.
In September, AbbVie assumed the same role on the PGA Tour. The partnership was centred on brain health, with donations for every score of one stroke under par – known as a ‘birdie’ in golf.
AbbVie is just one of several pharma companies to join the sporting world this year. Amgen, Sanofi, and Bristol Myers Squibb (BMS) were all on show at this year’s FIFA World Cup, hosted jointly by the US, Mexico, and Canada, via city partnerships and ad campaigns. Novartis is the NFL’s first pharmaceutical partner, Eli Lilly is partnered with the US Olympic team, and Sanofi is a partner to the Tour de France.
The US is the only country besides New Zealand that allows direct advertising of prescription drugs to consumers. Despite a tightening of regulation under the Trump administration, it remains an important commercial avenue for the pharmaceutical sector in the country. The use of celebrity ambassadors is also a common sight in healthcare marketing.
But there are no rules in the US or other countries that bar a drug company itself from sponsoring sports teams, leagues, or events, provided no product is specifically advertised.
Zak Brown, McLaren Racing’s CEO, sums up the trend: “At first glance, medicine and motorsport may seem like different worlds, but we’re united by a shared commitment to driving innovation.”
